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Background: This year marks the twentieth anniversary of the approval by the US Food 
and Drug Administration of interleukin-2 (IL2) for use in cancer therapy, initially for renal 
cell carcinoma and later for melanoma. IL2 therapy for cancer has stood the test of time, with 
 continued widespread use in Europe, parts of Asia, and the US. Clinical complete responses are 
variably reported at 5%–20% for advanced malignant melanoma and renal cell carcinoma, with 
strong durable responses and sustained long-term 5–10-year survival being typical if complete 
responses are generated.
Methods: The literature was reviewed for the actions and clinical effects of IL2 on subsets of 
T cells. The influence of IL2 on clinical efficacy was also sought.
Results: The review revealed that IL2 is capable of stimulating different populations of T cells in 
humans to induce either T effector or T regulatory responses. This apparent “functional  paradox” 
has confounded a clear understanding of the mechanisms behind the clinical effects that are 
observed during and following administration of IL2 therapy. An average complete response 
rate of around 7% in small and large clinical trials using IL2 for advanced renal cell carcinoma 
and malignant melanoma has been shown from a recent review of the literature.
Conclusion: This review considers the published literature concerning the actions and emerging 
clinical effects of IL2 therapy, spanning its 20-year period in clinical use. It further details some 
of the recently described “bimodal” effects of IL2 to explain the apparent functional paradox, 
and how IL2 might be harnessed to emerge rapidly as a much more effective and predictable 
clinical agent in the near future.
Keywords: interleukin-2, cancer therapy, immunotherapy, immune response, translational 
research, cytokines, regulatory T cells, immune modulation, complete responses, bimodal role
Introduction
Interleukin-2 (IL2) was originally described as an integral T cell growth factor 
necessary for activation and expansion of T cell populations in vitro and in vivo. It was 
cloned and synthesized in the early 1980s for laboratory use1 and then subsequently 
trialed and utilized for human therapy, notably for advanced malignant melanoma and 
renal cell carcinoma, but has been used for a variety of other cancer types as well, 
including colorectal, breast, and lung carcinomas, and for mesothelioma. Isolated 
complete responses have been noted in these cancer types as well, but the larger and 
more numerous trials have occurred in malignant melanoma and renal cell carcinoma.2 
It is the experience in these cancers which we will focus on.
IL2 is a current treatment option for patients with late-stage renal cell carcinoma 
and those with malignant melanoma. Notably, complete responses, where no evidence 
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of detectable cancer remains in the patient, are reported 
relatively consistently using IL2 therapies. Complete 
responses are often durable and associated with long-term 
survival. IL2 has a remarkable sustained history, being 
initially approved for clinical use in 1992.2 Back in those 
days, IL2 was thought to stimulate or initiate the immune 
response via its stimulation of T effector cells, often being 
called the “master cytokine”.
Recently, IL2 therapy has been advanced as a potential 
immune modulator able to “tweak” the immune response 
selectively to aid transplant tolerance, whilst others reported 
this in graft versus host disease and chronic hepatitis C 
infection.3–5 The notion of IL2 possessing a “dual capacity” 
to promote both activation and tolerance has remained enig-
matic and perplexing for some time. Some important issues 
concerning the earlier reported dual role of IL2 appear to have 
been somewhat overlooked in much of the understanding, 
research, and argument surrounding the actions and current 
clinical use of IL2.
The literature has repeatedly described the effects of 
IL2 on T effector cells as causing rapid T cell expansion, 
with subsequent activation or augmentation of an immune 
response in vitro or in vivo. However, recent attention has 
also been paid to the capacity of IL2 to stimulate T regulatory 
cells in a manner analogous to that of T effector cells, 
pointing to an apparent paradoxical role of IL2 as a cytokine 
that has the capacity to drive the immune response in both 
an activated and an inhibitory direction.6–11 The aim of this 
research was to explore how this apparent paradox can be 
explained.
Materials and methods
The literature was reviewed for the actions and clinical 
effects of IL2 on T cell subsets. The influence of IL2 on 
clinical efficacy was also sought. Search methods included 
the PubMed, Medline, Google Scholar, and associated data 
bases, using the terms “interleukin-2”, “IL2”, “complete 
response”, “clinical trial”, “clinical responses”, “survival”, 
“T cells”, “T effector cells”, “T regulatory cells”, 
“cancer”, “melanoma”, “renal cell cancer”, and “renal cell 
carcinoma”.
Results and discussion
The literature to date includes numerous studies demonstrating 
dual roles for IL2 in activating and inhibiting immune 
responses,6–11 and in producing a range of clinical responses, 
including a small but important proportion of complete 
clinical responses.2,6–8
Paradoxical bimodal role of iL2  
in immune homeostasis
The literature indicates that IL2 is now recognized as being 
responsible not only for initiating the immune response, but 
also for the homeostatic termination of that same immune 
response by stimulating T regulatory cells. Therefore, it 
is a “bimodal” cytokine with dual actions and opposing 
results in the time domain.3–5,9–15 Therefore, we reason that 
it is this functional “bimodality” which has created a most 
confounding paradox for medical science and no doubt 
slowed accurate and successful clinical application of IL2.
“How wonderful that we have met with a paradox. 
Now we have some hope of making progress” – Niels Bohr 
(1885–1962) Danish physicist.
The immune response once triggered, is known to be 
a sequential, time-dependent, homeostatic, physiological 
process. It is truly “dynamic”, not static, as widely viewed 
previously. This process requires the coordinated and timely 
interaction of cytokines, their receptors, and the responding 
cell populations. These cytokine/receptor interactions have 
half-lives of minutes to hours. The resulting coordinated, 
sequential, clonal cellular expansions can take several 
days to rise and fall. This gives rise to the initiation and 
then termination of that response. We know this from our 
experience with vaccinology, and induction of the acute 
immune response with a rise then fall over several days.11
Both T effector cells and T regulatory cells transiently 
express the IL2 receptor for only about 8–12 hours, and both 
require IL2 for their activation/expansion and maintenance 
(Figures 1 and 2). Recently, McNally et al described the 
existence of an IL2 “feedback loop” between T effector 
cells and T regulatory cells, which can homeostatically 
promote or limit the intensity, respectively, of the immune 
response.12 Further, both of these opposing arms of the 
immune response are exquisitely sensitive to IL2, including 
both endogenous and exogenous (therapeutic) IL2 sources. 
In addition, Knoechel et al previously described the sequential 
development of T effector cells and then T regulatory cells 
under the influence of IL2 in an autoimmune mouse model.10 
These observations were in the acute state, but little has 
been done to monitor closely and sequentially map the 
immune response in the chronic state using serial daily 
measurements.
iL2 therapy in cancer
Since 1992, repeated trials using IL2 have delivered 
complete response rates which have remained remarkably 
consistent at approximately 7% in two very different 
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(embryologically derived) advanced cancer types, namely 
renal cell carcinoma (mesodermal) and malignant mela-
noma (neural crest).2,6–8,16 Although complete responses 
occur randomly and unpredictably in a trial population, 
the approximate average 7% complete response barrier 
has been fixed across many years in both large and small 
clinical trials. This has been difficult to comprehend clini-
cally until now.
Of major clinical importance is that many of these 
complete responses have been durable, out beyond 
10 years. With our current and emerging understanding 
of the suppressed tumor-specific immune response in the 
cancer patient, IL2 when efficacious, clearly appears to be 
successfully manipulating a pre-existing or endogenous 
antitumor immune response in these few lucky patients. 
Indeed, with IL2 therapy alone, no tumor antigen is being 
supplied. How can we make complete responses a reality for 
most or all patients?
In the case of IL2 therapy for renal cell carcinoma and 
malignant melanoma, the schedule of high-dose infusions over 
15 minutes intermittently every 8 hours for up to 4–5 days 
(with a break of a number of days before repeating)2,6–8,16 
has probably evolved clinically to overcome the natural 
physiological IL2/IL2R half-life restrictions, and the narrow 
time-dependent influence of IL2 on the effector arm of the 
tumor immune response, while also attempting to reduce 
toxicity. This evolution occurred perhaps without due 
appreciation in the past of the biological bimodal activatory/
proinflammatory, then immune regulatory/inhibitory function 
of IL2, in the time domain. Consequently, it is not surprising 
that IL2 is only successful therapeutically in a minority of 
patients, ie, some 7% or so. Moreover, some investigators have 
observed effective clinical responses using intermittent short 
bolus IL2 dosing, rather than longer IL2 infusions.2,17
Historically, cytokine and cellular subpopulation 
measures of immune reactivity have been used in an ad hoc 
fashion and intermittently to observe points in time during 
therapy. This has perhaps led to some misleading inferences 
about how the immune system is behaving at the time of 
therapy and afterwards in the cancer patient. Interpretation 
of the interaction between the immune dynamics during 
IL2 therapy under the influence of chronic tumor antigen 
exposure has been greatly lacking. This is because regular, 
frequent, serial daily measurements of inflammation or 
immune reactivity have largely not been done in the past, 
either before, during, or after therapy. This has meant that 
detailed information concerning the timing of therapy and 
the effects of therapeutic interventions has not been able 
IL2R,  relative level / density
IL2R Expression T-eff Activation  
/ Expansion
Time (several days)












Figure 1 Progressive interleukin-2 (iL2R) receptor expression over time on T effector cells then regulatory T cells, and respective time-dependent activation of effector 
cells and regulatory cells. 
Notes: This sequential rise and fall of receptor density and expansion of alternating opposing T cell populations creates the homeostatic feedback loop of initiation then 
termination of the immune response. These cytokine and cellular kinetics are well described in the literature. The relative “refractory” period is predicted from the literature 
and biological principles observed in other systems, where restimulation is impeded.
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to be elucidated or appreciated fully in terms of clinical 
outcome.
Therapeutic observations from  
the preclinical iL2 mouse model
Since the mid 1980s, when the first published preclinical 
accounts of the immune modulatory effects of IL2 were 
reported, a number of researchers have noticed a timing 
effect with respect to IL2 administration and efficacy of 
therapy.18–21 This led Shrikant and Mescher in 2002 to 
comment, “The timing and extent of exposure to IL-2 
can clearly have dramatic effects on whether or not it is 
efficacious in activating, or reactivating, tumor-specific 
CD8+ T cell responses, making it difficult to know how to use 
it clinically in an optimal manner”.20 In addition, Knoechel 
et al commented, “the timing of administration may be the 
key to its successful clinical application”.10 However, no 
method to achieve this for maximum therapeutic benefit in 
the human situation appears to have been offered to date, 
despite the afore mentioned observations indicating timing 
was important.
Furthermore, more recently, Feinerman et al have 
demonstrated with their T effector/T regulatory cell modeling 
system at the single cell level that the timing and molecular 
surface density of IL2/IL2 receptor interaction are significant 
contributors to discrimination between self and nonself.22 How 
these factors play out at the whole tissue/systemic level is less 
well known, and again serial daily measurements are likely to 
hold many of the crucial answers. These preclinical data strongly 
suggest that the cell types predominantly expressing the IL2 
receptor at the time of treatment with IL2, ie, T regulatory cells 
and T effector cells, will determine the direction in which the 
immune response is driven (Figures 1 and 2).
We posit that artificiality of the mouse IL2 experiments 
increased the probability of a successful therapeutic outcome. 
We suspect a convenient timeframe (in days) between 
primary tumor inoculation and initiation of therapy favored 





























Window for therapeutic IL2 delivery to optimally augment the anti-cancer immune response
Figure 2 Alternating interleukin-2 “feedback” induced homeostatic oscillation of T effector cells followed by T regulatory cells. 
Notes: This “functional unit” of the (acute) immune response consists of responsiveness, then tolerance, to antigen stimulation. Chronic antigen persistence and stimulation 
produces the observed alternating inflammatory/immune oscillation or cycle (upper figure). The repeating cycle is hypothesized to create recurring narrow therapeutic 
windows (of approximately 12 hours wide) where the immune response can be driven in the direction of responsiveness or tolerance. The typical sigmoidal alternating 
T effector cell and T regulatory cell rapid sigmoidal expansion curves showing the predicted respective positions of maximal susceptibility for therapeutic intervention using 
agents such as interleukin-2 (lower figure). On the basis of mathematical probability this potentially explains why timing of administration of IL2 therapy may ultimately govern 
and restrict complete response efficacy to approximately 7% of patients.
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tumor regression), and regulatory/immune suppression 
(tolerogenic) at later time points in animals that experienced 
disease progression.
These conflicting and confounding observations can 
now be explained in light of the contemporary appreciation 
of the discrete, time-dependent, and opposing dual or 
“bimodal” role that IL2 plays in immune homeostasis and 
apparent chronic antigen stimulation.13 The implications of 
knowledge gained over 20 years has meant that the earlier 
preclinical and clinical experience of limited spectacular, but 
random, successes (complete responses) seen in late-stage 
cancer patients can now be explained rationally. This could 
potentially open up the way for redesigning the IL2 protocols 
to maximize efficacy in most patients.
Other mechanisms could explain the historic nature and 
spectrum of random responses seen in late-stage cancer 
patients treated with IL2. Genetic variations in tumors and in 
individual patient immune constitution/capability have been 
investigated in attempts to either predict responses or select 
patients for therapy. Although several factors, such as low 
serum levels of fibronectin and vascular endothelial growth 
factor, have been associated with improved responses to IL2, 
it has remained difficult to predict responders.23,24
Perhaps the simplest explanation for random efficacy, 
namely the timing of therapy, is the easiest to explore with 
the greatest immediate translational potential. This has been 
largely overlooked in human clinical application, despite it 
clearly playing a role in the earlier mouse experiments. The 
recent advances in our understanding of immune homeostasis 
and the bimodal attributes of IL2 suggests researchers should 
be looking more closely and accurately at the “time domain”. 
Single time-point or limited sampling analysis is clearly 
inadequate for accurately mapping a dynamic physiological 
process (the immune response) that is known to operate 
homeostatically and sequentially in minutes, hours, days, 
and weeks. As an example, imagine how our understanding 
would have been retarded in mapping the hormonal kinetics 
or transcriptional profile of the menstrual cycle with only one 
or two blood samples taken from 100 fertile women.
iL2 and iL2 receptors and cancer cells
Other factors that have confounded our understanding of the 
roles of IL2 in cancer have been the knowledge that in some 
situations either IL2 and/or IL2 receptors can be released or 
expressed by cancer cells themselves.25–29 How this affects 
the growth of cancers in vivo and how it interplays with 
exogenous IL2 therapies is currently unclear. However, the 
broad aim of exogenous IL2 therapy is to coordinate effector 
T cell immune responses to enhance the pre-existing antitu-
mor immune response direction towards that of killing cancer 
cells. Therefore, evaluation of IL2 and IL2R expression on 
tumor cells from biopsies prior to therapy might potentially 
be of clinical relevance.
wider role of iL2 in chronic disease
Our work suggests that under a chronic persistent tumor 
antigen load, as exists for a late-stage surgically nonresectable 
cancer patient, the IL2 feedback loop described by McNally 
et al12 continuously oscillates between a state of activation 
and suppression.30–34 In essence, what happens in the acute 
inflammatory state simply repeats itself continuously unless 
antigen is removed from the system. Therefore, it is not 
unreasonable to speculate that due to the time-dependent, 
bimodal functions of IL2 and the IL2 receptor, the time and 
dose could influence the clinical outcome in different disease 
states, ie, cancer, autoimmunity, chronic infections, and 
transplantation, as also described previously in the mouse 
experiments.
Improving clinical efficacy of IL2 therapy
We suggest that because IL2 is capable of driving the 
immune system in either of two opposing directions, namely 
either responsiveness/activation or tolerance/inhibition, 
the timing of IL2 administration with respect to the status 
of immune system dynamics at the time of administration 
will critically direct the immune response and determine 
outcome. The influence of any underlying natural bimodal 
homeostatic dynamic will therefore likely be the critical 
principal determinant of clinical efficacy. We suspect that 
the way forward, at least for cancer therapy, will be to 
analyze accurately the patient’s underlying tumor immune 
response in a serial manner, then appropriately and accurately 
synchronize therapy with immune fluctuation.15,30–34 This 
time-dependent dynamic aspect of the immune response in 
the cancer patient has been largely overlooked in the past, and 
has prevented us from being able to observe how our in vivo 
therapeutic approaches are influencing the immune response 
to produce the observed clinical effects. Indeed, this logic 
might also be expected to apply to administration of other 
immunotherapeutic agents, such as CTLA4 antibodies or 
vaccines, to improve their clinical efficacy.16,32,36 In addition, 
the notion of timing and immune responsiveness may apply 
more widely to many other therapies.35
Specifically, the pattern of the intrinsic fluctuation in the 
patient’s individual immune response can be determined 
by measuring serum inflammatory markers, eg, C-reactive 
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protein daily or near daily over a 2–3-week time period. 
Once these fluctuations are known, IL2 therapy can then 
be carefully delivered in a synchronized pulse, and at 
the predicted time when T effector cells are maximally 
expressing the IL2 receptor and T regulatory cells are 
not (Figures 1 and 2). The aim of this discrete approach 
is to avoid the T regulatory phase in order to engineer an 
extended,  predominant T  effector response in the cancer 
patient to achieve maximum clinical benefit. This would 
effectively counter the repetitive homeostatic attenuation 
of the immune response that arises from chronic persistent 
antigen load and stimulation. For autoimmune disease control 
and transplantation/graft acceptance, the opposite approach 
with careful enhancement of T regulatory function might 
well apply.
Conclusion
Since the cloning of IL2 about 30 years ago, and its 
clinical introduction and regulatory approval as an immune 
stimulatory agent some 20 years ago, the complete response 
rate in two different advanced cancers in both small and 
large clinical trials has remained remarkably constant at 
about 7%.2,16 Over that time, our understanding of the 
apparent paradoxical bimodal/opposing proinflammatory 
and immune regulatory influence of IL2 on the immune 
response has emerged. This bimodal role of IL2, together 
with considerable clinical experience with IL2 therapy, 
potentially explains why some patients respond and others 
do not.
We propose that a way forward to resolve this long-
standing randomly “locked” low clinical efficacy is by serially 
monitoring each patient, then synchronizing the administration 
of IL2 in time, to match the homeostatic fluctuations in the 
late-stage cancer patient’s immune response.15,35 In doing 
this, we also propose that the bimodal activity of IL2 can be 
harnessed and modulated towards bulk activation of antitumor 
effector cells to produce a substantial increase in the complete 
response rate. Thus, generation of far more predictable, 
reliable clinical responses and improved long-term survival 
for patients can be engineered.
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